Evidence map›Paper›PMID 30106092›Full record

ArticleInternational journal of molecular medicine2018

miR‑204‑5p inhibits the occurrence and development of osteoarthritis by targeting Runx2.

Jiaqing Cao, Xinyou Han, Xin Qi, Xiangyun Jin, Xiaolin Li

Open access · hybridAbstract read
In one paragraph

Article in International journal of molecular medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. LINC00922 acts as a novel oncogene in gastric cancer.World journal of surgical oncology · 2022
    Article
  9. Modulation of miR-204 Expression during Chondrogenesis.International journal of molecular sciences · 2022
    Article
  10. Article
  11. Review
  12. Crosstalk Among circRNA/lncRNA, miRNA, and mRNA in Osteoarthritis.Frontiers in cell and developmental biology · 2021
    Review
  13. Article
  14. Runx2 plays a central role in Osteoarthritis development.Journal of orthopaedic translation · 2020
    Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Jiaqing CaoDepartment of Orthopedic Surgery, The Sixth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai 200233, P.R. China.
Xinyou HanDepartment of Orthopedic Surgery, The Sixth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai 200233, P.R. China.
Xin QiDepartment of Orthopedic Surgery, The Sixth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai 200233, P.R. China.
Xiangyun JinDepartment of Orthopedic Surgery, The Sixth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai 200233, P.R. China.
Xiaolin LiDepartment of Orthopedic Surgery, The Sixth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai 200233, P.R. China.
Shanghai Sixth People's Hospital · CNShanghai Jiao Tong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

One of the hallmarks of osteoarthritis (OA) development is endochondral ossification, in which Runt‑related transcription factor‑2 (Runx2) is aberrantly expressed. Runx2 was previously identified to be regulated by microRNA‑204‑5p (miR‑204‑5p). The aim of the present study was to investigate the potential function of miR‑204‑5p regulating Runx2 during the development of OA and the underlying molecular mechanism. The expression levels of miR‑204‑5p and Runx2 were determined in tissue specimens. Rat OA models were established by transecting the anterior and posterior cruciate ligaments and removing the meniscus. Rats were treated with miR‑204‑5p agomir and miR‑204‑5p negative control (NC). All in vitro experiments were performed using rat primary chondrocytes and the SW‑1353 human bone chondrosarcoma cell line. It was identified that the expression of miR‑204‑5p was significantly decreased, whereas Runx2 was significantly increased, in human OA tissues compared with in non‑OA tissues, and levels were inversely associated with each other in primary chondrocytes and chondrosarcoma cells. Overexpression of miR‑204‑5p decreased the proliferation of chondrocytes and SW‑1353 cells. Using a luciferase reporter assay, Runx2 was identified to be a direct target of miR‑204‑5p in chondrocytes and overexpressed miR‑204‑5p altered the expression of collagens II, X and matrix metalloproteinase (MMP)‑1 and MMP‑13 in primary chondrocytes and SW‑1353 cells. Histological analysis revealed that miR‑204‑5p treatment ameliorated the OA‑like phenotype that is reflected by assessment of cartilage thickness and Mankin's score. Runx2 expression was gradually increased as the rats increased in age. At 10 weeks of miR‑204‑5p agomir treatment, altered expression levels of collagens II and X, cartilage oligomeric matrix protein fragment, aggrecan, MMP‑1 and MMP‑13 were observed in the treatment group compared with the NC group. In conclusion, the results of the present study indicated that miR‑204‑5p decreases chondrocyte proliferation and ameliorates the OA‑like phenotype in rats with surgically induced OA by targeting Runx2.

Indexed as

AgedAnimalsBlotting, WesternCell ProliferationCell SurvivalChondrocytesCore Binding Factor Alpha 1 SubunitFemaleHumansImmunohistochemistryMaleMatrix Metalloproteinase 1Matrix Metalloproteinase 13MicroRNAsMiddle AgedOsteoarthritisCore Binding Factor Alpha 1 SubunitMatrix Metalloproteinase 1Matrix Metalloproteinase 13MicroRNAsMIRN204 microRNA, human

Identifiers

PMID30106092
PMCPMC6192722
OpenAlexW2886405576

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.